UBS AM’s Amneal Pharmaceuticals AMRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.06M | Sell |
234,773
-14,589
| -6% | -$200K | ﹤0.01% | 1704 |
|
|
2026
Q1 | $3.1M | Buy |
249,362
+6,229
| +3% | +$83.6K | ﹤0.01% | 1820 |
|
|
2025
Q4 | $3.06M | Buy |
243,133
+9,238
| +4% | +$106K | ﹤0.01% | 1699 |
|
|
2025
Q3 | $2.34M | Sell |
233,895
-236,537
| -50% | -$2.12M | ﹤0.01% | 1683 |
|
|
2025
Q2 | $3.81M | Buy |
470,432
+135,476
| +40% | +$1.02M | ﹤0.01% | 1831 |
|
|
2025
Q1 | $2.81M | Buy |
334,956
+16,536
| +5% | +$138K | ﹤0.01% | 1837 |
|
|
2024
Q4 | $2.52M | Buy |
318,420
+99,866
| +46% | +$838K | ﹤0.01% | 1934 |
|
|
2024
Q3 | $1.82M | Sell |
218,554
-46,170
| -17% | -$361K | ﹤0.01% | 2083 |
|
|
2024
Q2 | $1.68M | Buy |
264,724
+228,295
| +627% | +$1.45M | ﹤0.01% | 2092 |
|
|
2024
Q1 | $221K | Buy |
+36,429
| New | +$205K | ﹤0.01% | 2445 |
|
|
2023
Q3 | – | Sell |
-84,912
| Closed | -$118K | – | 2593 |
|
|
2023
Q2 | $118K | Hold |
84,912
| – | – | ﹤0.01% | 2631 |
|
|
2023
Q1 | $118K | Hold |
84,912
| – | – | ﹤0.01% | 2631 |
|
|
2022
Q4 | $169K | Hold |
84,912
| – | – | ﹤0.01% | 2463 |
|
|
2022
Q3 | $172K | Sell |
84,912
-14,073
| -14% | -$39.4K | ﹤0.01% | 2633 |
|
|
2022
Q2 | $315K | Hold |
98,985
| – | – | ﹤0.01% | 2470 |
|
|
2022
Q1 | $413K | Hold |
98,985
| – | – | ﹤0.01% | 2524 |
|
|
2021
Q4 | $474K | Hold |
98,985
| – | – | ﹤0.01% | 2580 |
|
|
2021
Q3 | $529K | Hold |
98,985
| – | – | ﹤0.01% | 2478 |
|
|
2021
Q2 | $507K | Buy |
98,985
+12,036
| +14% | +$68.4K | ﹤0.01% | 2530 |
|
|
2021
Q1 | $585K | Sell |
86,949
-2,656
| -3% | -$14.7K | ﹤0.01% | 2331 |
|
|
2020
Q4 | $409K | Sell |
89,605
-24,909
| -22% | -$110K | ﹤0.01% | 2353 |
|
|
2020
Q3 | $444K | Hold |
114,514
| – | – | ﹤0.01% | 2191 |
|
|
2020
Q2 | $545K | Sell |
114,514
-2,214
| -2% | -$9.12K | ﹤0.01% | 2089 |
|
|
2020
Q1 | $406K | Buy |
116,728
+31,191
| +36% | +$132K | ﹤0.01% | 2051 |
|
|
2019
Q4 | $412K | Sell |
85,537
-20,939
| -20% | -$72.8K | ﹤0.01% | 2300 |
|
|
2019
Q3 | $309K | Buy |
106,476
+15,769
| +17% | +$55K | ﹤0.01% | 2450 |
|
|
2019
Q2 | $650K | Buy |
90,707
+33,033
| +57% | +$338K | ﹤0.01% | 2086 |
|
|
2019
Q1 | $817K | Buy |
57,674
+20,827
| +57% | +$275K | ﹤0.01% | 1898 |
|
|
2018
Q4 | $499K | Sell |
36,847
-13,514
| -27% | -$244K | ﹤0.01% | 1997 |
|
|
2018
Q3 | $1.12M | Buy |
50,361
+20,163
| +67% | +$424K | ﹤0.01% | 1770 |
|
|
2018
Q2 | $496K | Buy |
+30,198
| New | +$530K | ﹤0.01% | 2099 |
|
Other funds holding AMRX
TGA
RCMNY
UBS AM's AMRX Position: Q2 2026 in Review
UBS AM reduced its Amneal Pharmaceuticals (AMRX) stake by 5.9% in Q2 2026, selling an estimated $200K and leaving 234,773 shares worth $4.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1704.
UBS AM first reported a position in AMRX in Q2 2018 and has held it in 31 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.
- UBS AM held 234,773 shares of Amneal Pharmaceuticals worth $4.06M as of Q2 2026.
- UBS AM sold 14,589 Amneal Pharmaceuticals shares in Q2 2026, an estimated $200K.
- Amneal Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1704 holding.
- UBS AM first reported a position in Amneal Pharmaceuticals in Q2 2018 and has held it in 31 quarters since.
- 310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.